COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LD5B
|
|||
| Drug Name |
Ribavirin + lopinavir + ritonavir + interferon alfa-2a
|
|||
| Synonyms |
Rebetol + aluviran + norvir + roferon A
|
|||
| Drug Type |
Combination drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Investigative | [1], [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV 3C-like proteinase (3CLpro) | Target Info | Inhibitor | [3] |
| Lopinavir/ritonavir blocks viral replication of MERS-CoV via inhibiting the 3C-like protease (3CLpro). | ||||
| MERS-CoV RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [1] | |
| Ribavirin is a nucleoside against MERS-CoV. Its mechanism includes lethal mutagenesis of RNA virus genomes mediated by the MERS-CoV RNA-dependent RNA polymerase. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
| 2 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. | |||
| 3 | Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.